News
Imagine treating a genetic disease not by managing symptoms for life, but by correcting the underlying genetic error itself. Inventors at NIH are advancing that vision with a gene editing technology designed to deliver highly precise genetic corrections, opening new possibilities for therapies that
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal
1 in every 200 people with eye-related irritation in the US has uveitis. Vision loss can occur if the uveitis remains untreated, therefore, early detection is crucial. Certain uveitis cases currently require fluorescein angiography (FA) for diagnosis due to its ability to display retinal vascular
Current diagnostic tests for COVID-19 and other viruses require RNA extraction and analysis of the extracted RNA sample. NIH Inventors have developed a novel, improved sample preparation method that eliminates the need for an RNA extraction step. The inventors discovered that incorporating a